Lewis Gazzard

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

John A. Flygare, Maureen H. Beresini, Nageshwar Budha et al. · Journal of Medicinal Chemistry · 2012 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody–drug conjugates

Cary D. Austin, Xiaohui Wen, Lewis Gazzard et al. · Proceedings of the National Academy of Sciences · 2005 · 238 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Synthesis of the Kopsia alkaloids (±)-pauciflorine B, (±)-lahadinine B, (±)-kopsidasine, (±)-kopsidasine-N-oxide, (±)-kopsijasminilam and (±)-11-methoxykopsilongine

Philip Magnus, Lewis Gazzard, L. Hobson et al. · Tetrahedron · 2002 · 88 citations

Pharmacy, Chemistry, Medicinal Chemistry +5

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-p <i>K</i> _a Polar Moiety

Chudi Ndubaku, James J. Crawford, Joy Drobnick et al. · ACS Medicinal Chemistry Letters · 2015 · 86 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window

Joachim Rudolph, Lesley Murray, Chudi Ndubaku et al. · Journal of Medicinal Chemistry · 2016 · 77 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13